Penumbra, Inc. (PEN) is a medical device company focused on thrombectomy — the mechanical removal of blood clots. Its portfolio addresses acute ischemic stroke, pulmonary embolism (PE), deep vein thrombosis, and acute limb ischemia. The company is best known for computer-assisted aspiration technology, including its Lightning and Indigo systems, which are used to clear clots quickly in minimally invasive procedures. This niche sits at the center of one of the fastest-growing segments of cardiovascular medicine.
The $374 figure is not an arbitrary target. In January 2026, Boston Scientific (BSX) agreed to acquire Penumbra for approximately $14.5 billion, or $374 per share — a premium of roughly 19% to Penumbra's closing price before the announcement. Under the terms, Penumbra shareholders can elect to receive $374 in cash or 3.8721 Boston Scientific shares per Penumbra share, with total consideration split roughly 73% in cash and 27% in stock. The transaction is expected to close in 2026.
This makes the "Can Penumbra reach $374?" question fundamentally different from an ordinary price forecast. The target is effectively the deal consideration itself. Penumbra's stock trades below that level — around the low-to-mid $320s in recent sessions — because the market applies a discount for the time until closing and the residual risk that the deal could be delayed, renegotiated, or blocked.
Penumbra has traded within a 52-week range of roughly $221 to $362, with its all-time high near $362 reached in early 2026. Even after the acquisition announcement, shares have remained below the $374 deal price, reflecting a classic merger-arbitrage spread. Because a meaningful portion of the consideration is stock, the effective value of the deal moves with Boston Scientific's share price, adding another layer of variability to the path toward $374.
The clearest catalyst is successful completion of the transaction. If the deal clears regulatory review and closes on the announced terms, Penumbra shareholders would receive consideration equivalent to the agreed value, narrowing the current spread toward $374. Additionally, Penumbra's underlying business has shown solid momentum: revenue grew roughly 17% in 2025 to about $1.4 billion, with analysts projecting further growth into 2026 and beyond, driven by expanded adoption of thrombectomy in pulmonary embolism and international markets.
The main risks are tied to the deal itself rather than Penumbra's fundamentals. The transaction has drawn attention from regulators, and any extended antitrust review or request for concessions could delay closing. Because roughly 27% of the consideration is Boston Scientific stock, a decline in BSX shares would reduce the realized value of the mixed offer, even if the cash portion remains unchanged. If the deal were to fall apart, Penumbra's shares would likely fall back toward their standalone value, and the $374 level would become far less relevant.
Following the announcement, Wall Street's stance on Penumbra has converged around the deal. The consensus rating sits at Hold, with an average 12-month price target near $361–$364 and a high of $374. That high figure aligns almost exactly with the acquisition price, underscoring that analyst forecasts are now anchored to the transaction rather than an independent valuation of Penumbra's standalone growth.
From a technical perspective, the prior all-time high near $362 represents a key resistance level and the nearest meaningful hurdle before $374. The $374 level itself now functions as the practical ceiling implied by the deal. On the downside, the broader 52-week range and the low $300s have provided support as the market prices in deal execution risk.
Penumbra trades at a premium valuation, with a price-to-earnings (P/E) ratio well above the broader medical-device average, reflecting expectations for durable, above-market growth in thrombectomy. The acquisition price of roughly nine times estimated forward sales underscores how much Boston Scientific is paying for that growth runway. For most investors, the valuation debate has effectively been settled by the deal — the open question is execution, not fundamentals.
For traders monitoring how Penumbra reacts to deal-related news and market conditions, Tickeron's AI Daily Buy/Sell Signals offer an automated way to stay informed. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface new opportunities, track existing positions, and spot shifting market trends more efficiently. Those interested in a data-driven complement to their own research may find the tool worth exploring.
Whether Penumbra can reach $374 depends overwhelmingly on the Boston Scientific acquisition closing on its announced terms. The strongest argument in favor is the binding agreement itself, which explicitly values the company at $374 per share. The primary risks are regulatory review, the variable value of the stock component tied to Boston Scientific's share price, and the possibility of delay or renegotiation. Investors should monitor regulatory milestones, Boston Scientific's stock price, and any updates to the transaction's expected closing timeline. While the path to $374 appears well-defined, it is a path through a merger process, not an ordinary rally — and that distinction carries its own set of uncertainties.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PEN has been loosely correlated with HAE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PEN jumps, then HAE could also see price increases.
| Ticker / NAME | Correlation To PEN | 1D Price Change % | ||
|---|---|---|---|---|
| PEN | 100% | -0.02% | ||
| HAE - PEN | 43% Loosely correlated | +1.61% | ||
| ISRG - PEN | 42% Loosely correlated | +2.41% | ||
| MMSI - PEN | 35% Loosely correlated | -0.13% | ||
| SMTI - PEN | 34% Loosely correlated | -0.31% | ||
| ATRC - PEN | 33% Loosely correlated | +2.98% | ||
More | ||||
| Ticker / NAME | Correlation To PEN | 1D Price Change % |
|---|---|---|
| PEN | 100% | -0.02% |
| Medical/Nursing Services industry (141 stocks) | 6% Poorly correlated | +0.38% |
| Health Services industry (242 stocks) | 6% Poorly correlated | +0.38% |